Related Experiment Videos
Determinants of drug delivery and transport to solid tumors
1College of Pharmacy and James Cancer Hospital & Solove Research Institute, The Ohio State University, 500 West 12th Avenue, Columbus, OH 43210, USA. au.1@osu.edu
Abstract:
This presentation addresses the barriers and determinants and the importance of drug-induced apoptosis in drug transport and delivery to organs and solid tumors. In particular, we examined the roles of interstitial space, drug removal by capillaries, tissue structure and tissue composition on drug distribution. Drug transport in bladder tissues is described by the distributed model which combined monodimensional Fickian diffusion and first order removal of drug by the perfusing blood. Microscopic evaluation of the spatial drug distribution in bladder, prostate and tongue indicates heterogeneous drug distribution with large and erratic concentration gradient. In general, drug distribution favors interstitial space and vasculature, with little penetration in muscles. Drug penetration into 3-dimensional solid tumors is typically 5- to 10-fold slower than in monolayer cultures. The transport of highly protein-bound drugs such as paclitaxel and doxorubicin in a solid tumor is retarded by a high tumor cell density and enhanced by drug-induced apoptosis. Accordingly, the delivery of a highly protein-bound drug to cells in a solid tumor is affected by its apoptotic effects and is therefore determined by the drug concentration and the treatment duration, i.e. treatment schedule. Under in vitro and in vivo conditions, the delivery of highly protein-bound drugs to tumor can be enhanced by using a pretreatment that induces apoptosis and reduction in cell density, and by using treatment schedules designed to take advantage of these drug-induced changes in tumor tissue composition. In conclusion, in addition to the usual processes involved in drug transport such as distribution through vascular space, transport across microvessel walls, and diffusion through interstitial space in tumor tissue, other factors including tissue structure and composition and alteration by drug-induced apoptosis are important determinants of drug distribution in organs and solid tumors.
Insights
Drug-induced apoptosis significantly impacts drug delivery to solid tumors by altering tissue composition and cell density. Understanding these changes is crucial for optimizing drug transport and treatment schedules.
Area of Science:
- Pharmacology
- Biomedical Engineering
- Oncology
Background:
- Drug delivery to solid tumors is complex, influenced by tissue barriers and drug properties.
- Heterogeneous drug distribution is observed in various organs and tumors, favoring interstitial spaces and vasculature.
Purpose of the Study:
- To investigate the role of drug-induced apoptosis in modulating drug transport and delivery to organs and solid tumors.
- To examine how tissue structure, composition, and interstitial space affect drug distribution.
Main Methods:
- Utilized a distributed model combining Fickian diffusion and first-order drug removal by blood.
- Performed microscopic evaluation of spatial drug distribution in bladder, prostate, tongue, and solid tumors.
- Assessed the impact of drug-induced apoptosis and cell density on drug penetration in vitro and in vivo.
Main Results:
- Drug distribution is heterogeneous, with limited penetration into muscles and significantly slower transport in 3D tumors compared to monolayer cultures.
- High tumor cell density retards the transport of protein-bound drugs, while drug-induced apoptosis enhances it.
- Pretreatment inducing apoptosis and reducing cell density can improve drug delivery to tumors.
Conclusions:
- Tissue structure, composition, and drug-induced apoptosis are critical determinants of drug distribution beyond traditional transport processes.
- Optimizing drug delivery strategies requires considering apoptosis-mediated changes in tumor microenvironment.
- Tailored treatment schedules leveraging apoptosis-induced alterations can enhance the efficacy of highly protein-bound drugs in solid tumors.